• Medientyp: E-Artikel
  • Titel: Outcomes After Distal Pancreatectomy with Celiac Axis Resection for Pancreatic Cancer: A Pan-European Retrospective Cohort Study
  • Beteiligte: Klompmaker, Sjors; van Hilst, Jony; Gerritsen, Sarah L.; Adham, Mustapha; Teresa Albiol Quer, M.; Bassi, Claudio; Berrevoet, Frederik; Boggi, Ugo; Busch, Olivier R.; Cesaretti, Manuela; Dalla Valle, Raffaele; Darnis, Benjamin; De Pastena, Matteo; Del Chiaro, Marco; Grützmann, Robert; Diener, Markus K.; Dumitrascu, Traian; Friess, Helmut; Ivanecz, Arpad; Karayiannakis, Anastasios; Fusai, Giuseppe K.; Labori, Knut J.; Lombardo, Carlo; López-Ben, Santiago; [...]
  • Erschienen: Springer Science and Business Media LLC, 2018
  • Erschienen in: Annals of Surgical Oncology, 25 (2018) 5, Seite 1440-1447
  • Sprache: Englisch
  • DOI: 10.1245/s10434-018-6391-z
  • ISSN: 1068-9265; 1534-4681
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: Abstract Background Western multicenter studies on distal pancreatectomy with celiac axis resection (DP-CAR), also known as the Appleby procedure, for locally advanced pancreatic cancer are lacking. We aimed to study overall survival, morbidity, mortality and the impact of preoperative hepatic artery embolization (PHAE). Methods Retrospective cohort study within the European-African Hepato-Pancreato-Biliary-Association, on DP-CAR between 1-1-2000 and 6-1-2016. Primary endpoint was overall survival. Secondary endpoints were radicality (R0-resection), 90-day mortality, major morbidity, and pancreatic fistulae (grade B/C). Results We included 68 patients from 20 hospitals in 12 countries. Postoperatively, 53% of patients had R0-resection, 25% major morbidity, 21% an ISGPS grade B/C pancreatic fistula, and 16% mortality. In total, 82% received (neo-)adjuvant chemotherapy and median overall survival in 62 patients with pancreatic ductal adenocarcinoma patients was 18 months (CI 10–37). We observed no impact of PHAE on ischemic complications. Conclusions DP-CAR combined with chemotherapy for locally advanced pancreatic cancer is associated with acceptable overall survival. The 90-day mortality is too high and should be reduced. Future studies should investigate to what extent increasing surgical volume or better patient selection can improve outcomes.